Proposed Data Collections Submitted for Public Comment and Recommendations, 65219-65221 [2014-26030]
Download as PDF
<![CDATA[
65219
Federal Register / Vol. 79, No. 212 / Monday, November 3, 2014 / Notices
may have resulted in undocumented
radiation exposures, characterizing
radiological protection and monitoring
practices, and identify co-workers and
other witnesses as may be necessary to
confirm undocumented information. In
this process, NIOSH uses a computer
assisted telephone interview (CATI)
system, which allows interviews to be
conducted more efficiently and quickly
as opposed to a paper-based interview
instrument. Both interviews are
voluntary and failure to participate in
either or both interviews will not have
a negative effect on the claim, although
voluntary participation may assist the
claimant by adding important
information that may not be otherwise
available. NIOSH is requesting a three
year approval for these data collection
activities.
information to provide to NIOSH about
the claim at this time. The form notifies
the claimant that signing the form
allows NIOSH to forward a dose
reconstruction report to DOL and to the
claimant, and closes the record on data
used for the dose reconstruction.
Signing this form does not indicate that
the claimant agrees with the outcome of
the dose reconstruction. The dose
reconstruction results will be supplied
to the claimant and to the DOL, the
agency that will utilize them as one part
of its determination of whether the
claimant is eligible for compensation
under the Act. It is estimated that 8,400
claimants will complete the conclusion
form which takes approximately 5
minutes per response.
The total estimated burden hours are
4,900. There is no cost to respondents
other than their time.
NIOSH uses the data collected in this
process to complete an individual dose
reconstruction that accounts, as fully as
possible, for the radiation dose incurred
by the employee in the line of duty for
DOE nuclear weapons production
programs. After dose reconstruction,
NIOSH also performs a brief, voluntary
final interview with the claimant to
explain the results and to allow the
claimant to confirm or question the
records NIOSH has compiled. This will
also be the final opportunity for the
claimant to supplement the dose
reconstruction record. Approximately
4,200 claimants will be interviewed
with an average burden of one hour per
response.
At the conclusion of the dose
reconstruction process, the claimant
submits a conclusion form to confirm
that the claimant has no further
ESTIMATED ANNUALIZED BURDEN HOURS
Number of
responses per
respondent
Number of
respondents
Average
burden per
response
(in hours)
Total burden
hours
Type of respondent
Form name
Claimant ............................................
Claimant ............................................
Initial interview ..................................
Conclusion form OCAS–1 ................
4,200
8,400
1
1
1
5/60
4,200
700
Total ...........................................
...........................................................
........................
........................
........................
4,900
Leroy A. Richardson,
Chief, Information Collection Review Office,
Office of Scientific Integrity, Office of the
Associate Director for Science, Office of the
Director, Centers for Disease Control and
Prevention.
[FR Doc. 2014–26032 Filed 10–31–14; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[60-Day 15–15CK]
mstockstill on DSK4VPTVN1PROD with NOTICES
Proposed Data Collections Submitted
for Public Comment and
Recommendations
The Centers for Disease Control and
Prevention (CDC), as part of its
continuing effort to reduce public
burden, invites the general public and
other Federal agencies to take this
opportunity to comment on proposed
and/or continuing information
collections, as required by the
Paperwork Reduction Act of 1995. To
request more information on the below
proposed project or to obtain a copy of
the information collection plan and
instruments, call 404–639–7570 or send
VerDate Sep<11>2014
17:37 Oct 31, 2014
Jkt 235001
comments to Leroy A. Richardson, 1600
Clifton Road, MS–D74, Atlanta, GA
30333 or send an email to omb@cdc.gov.
Comments submitted in response to
this notice will be summarized and/or
included in the request for Office of
Management and Budget (OMB)
approval. Comments are invited on: (a)
Whether the proposed collection of
information is necessary for the proper
performance of the functions of the
agency, including whether the
information shall have practical utility;
(b) the accuracy of the agency’s estimate
of the burden of the proposed collection
of information; (c) ways to enhance the
quality, utility, and clarity of the
information to be collected; (d) ways to
minimize the burden of the collection of
information on respondents, including
through the use of automated collection
techniques or other forms of information
technology; and (e) estimates of capital
or start-up costs and costs of operation,
maintenance, and purchase of services
to provide information. Burden means
the total time, effort, or financial
resources expended by persons to
generate, maintain, retain, disclose or
provide information to or for a Federal
agency. This includes the time needed
to review instructions; to develop,
acquire, install and utilize technology
PO 00000
Frm 00045
Fmt 4703
Sfmt 4703
and systems for the purpose of
collecting, validating and verifying
information, processing and
maintaining information, and disclosing
and providing information; to train
personnel and to be able to respond to
a collection of information, to search
data sources, to complete and review
the collection of information; and to
transmit or otherwise disclose the
information. Written comments should
be received within 60 days of this
notice.
Proposed Project
Improving the Impact of Laboratory
Practice Guidelines (LPGs): A New
Paradigm for Metrics—College of
American Pathologists—NEW—Center
for Surveillance, Epidemiology and
Laboratory Services (CSELS), Centers for
Disease Control and Prevention (CDC).
Background and Brief Description
The Centers for Disease Control and
Prevention is funding three 5-year
projects collectively entitled ‘‘Improving
the Impact of Laboratory Practice
Guidelines: A New Paradigm for
Metrics’’. An ‘‘LPG’’ is defined as
written recommendations for voluntary,
standardized approaches for medical
laboratory testing that takes into account
processes for test selection, sample
E:\FR\FM\03NON1.SGM
03NON1
65220
Federal Register / Vol. 79, No. 212 / Monday, November 3, 2014 / Notices
procurement and processing, analytical
methods, and results reporting for
effective diagnosis and management of
disease and health conditions. LPGs
may be disseminated to, and used by,
laboratorians and clinicians to assist
with test selection and test result
interpretation. The overall purpose of
these cooperative agreements is to
increase the effectiveness of LPGs by
defining measures and collecting
information to inform better LPG
creation, revision, dissemination,
promotion, uptake, and impact on
clinical testing and public health. The
project will explore how these processes
and their impediments and facilitators
differ among various intended users of
LPGs. Through this demonstration
project, CDC seeks to understand how to
customize LPG creation and promotion
to better serve these intended users of
LPGs. An important goal is to help
organizations that sponsor the
development of LPGs create a
sustainable approach for continuous
quality improvement to evaluate and
improve an LPG’s impact through better
collection of information.
The CDC selected three organizations
that currently create and disseminate
LPGs to support activities under a
cooperative agreement funding
mechanism to improve the impact of
their LPGs. The American Society for
Microbiology, the Clinical and
Laboratory Standards Institute, and the
College of American Pathologists (CAP),
will each use their LPGs as models to
better understand how to improve
uptake and impact of these and future
LPGs. Only the CAP submission will be
described in this notice.
The CAP project will address two
LPGs that are important to clinical
testing: immunohistochemistry test
validation (IHC) and an algorithm for
diagnosing acute leukemia (ALA). The
ALA LPG is being co-developed with
the American Society of Hematologists
(ASH). The intended users of the CAP’s
IHC LPGs will include pathologists,
clinical laboratory directors, and
laboratory managers overseeing the IHC
staining department. For the CAP’s ALA
LPG the intended users are pathologists
hematopathologists will be invited to
participate. The CAP hopes to achieve
an 80% response rate with their
individual data collections, or 880 (80%
× 1100 pathologists listed in the CAP
database).
The baseline survey for the ALA
guideline includes questions about
individual practices for diagnosing
various types of acute leukemia and
individual and laboratory reporting
practices. The link to the baseline
survey for the ALA guideline will be
disseminated via email to
hematopathologists in CAP’s database,
who will be provided a link to the
Qualtrics site that hosts the survey.
The CAP and CDC will strive to
ensure a high response rate for their IHC
and ALA surveys. CAP plans to
advertise both surveys. Similarly, the
CAP plans to maximize response rates
for non-CAP-accredited laboratories by
sending reminders through the US
postal system. The CAP will also try to
maximize response rates for the ALA
survey by advertising it through various
channels.
For burden calculation, we assume
one response per laboratory. We assume
respondents for the IHC survey will
include (1) pathologists, (2) laboratory
directors, and (3) other laboratory
managers of IHC laboratories, which
may consist of graduate level scientists
(Ph.D.s and Masters level),
approximately in a 25%:25%:50%
distribution, respectively. We assume
respondents for the ALA surveys will
include pathologists and hematologists
that sign out cases, approximately in a
95%:5% distribution, respectively.
The IHC baseline survey, which was
conducted prior to this CAP–CDC
cooperative agreement, took 15 minutes
to complete. The IHC postdissemination survey and the ALA
baseline survey are also expected to take
15 minutes. Each survey will be pilot
tested with nine or fewer respondents
before deployment to assure that they
require 15 minutes or less to complete.
CDC is requesting a one-year OMB
approval to collect the information.
There are no costs to respondents other
than their time.
and hematologists overseeing testing for
acute leukemia. Thus, all these
professionals will be surveyed by CAP.
Prior to entering into this cooperative
agreement project with the CDC, the
CAP had already completed a baseline
IHC LPG information collection from
laboratories that used IHC testing.
Subsequent to this data collection, the
CAP created and disseminated an IHC
LPG in a peer reviewed journal. Because
of this prior baseline assessment, the
CAP will only need to collect postdissemination data. For their ALA LPG
CAP/ASH Algorithm for Initial Work-Up
of Acute Leukemia, the CAP will
conduct both a baseline and a postdissemination survey. Because there are
uncertainties concerning the specific
focus group probes for the IHC LPG and
the ALA LPG, this notice only provides
a description of our collection of postdissemination information for the IHC
LPG and the baseline ALA LPG.
The CAP hopes to achieve an 80%
response rate, or 2,668 out of 3,335
potential respondents. This represents
laboratories known to be currently
performing IHC testing based upon their
participation in CAP’s IHC proficiency
testing (PT) program and 450 additional
laboratories identified by CDC using
previous CMS Part B reimbursement
claims for IHC testing. The response rate
for the baseline IHC survey was
approximately 70% but through more
focused promotion the CAP hopes to
increase participation. We have
identified a total of 3,335 (2,885 CAPaccredited + 450 non-CAP-accredited)
laboratories that will be targeted by the
IHC post-dissemination survey.
CAP-accredited laboratories that are
enrolled in IHC PT will receive surveys
with their PT mailings. Non-CAPaccredited laboratories will be surveyed
via the US postal system, with a faxback mechanism.
The CAP will need to collect both
baseline and post-guideline
dissemination data for the ALA LPG.
CAP will allow only one response per
computer internet protocol address. The
CAP has a database of pathologists who
have indicated specialization in
hematopathology; these
mstockstill on DSK4VPTVN1PROD with NOTICES
ESTIMATED ANNUALIZED BURDEN HOURS
Type of respondent
Form
name
Pathologist ..........................................................................................
IHC
ALA
IHC
IHC
ALA
Laboratory Directors ...........................................................................
Laboratory Managers ..........................................................................
Hematologist .......................................................................................
VerDate Sep<11>2014
17:37 Oct 31, 2014
Jkt 235001
PO 00000
Frm 00046
Fmt 4703
Number of
respondents
Sfmt 4703
Number of
responses per
respondent
834
1,045
834
1,667
55
E:\FR\FM\03NON1.SGM
1
2
1
1
2
03NON1
Average
burden per
response
(in hours)
15/60
15/60
15/60
15/60
15/60
Total burden
hours
209
523
209
417
28
Federal Register / Vol. 79, No. 212 / Monday, November 3, 2014 / Notices
65221
ESTIMATED ANNUALIZED BURDEN HOURS—Continued
Total .............................................................................................
Leroy A. Richardson,
Chief, Information Collection Review Office,
Office of Scientific Integrity, Office of the
Associate Director for Science, Office of the
Director, Centers for Disease Control and
Prevention.
Number of
respondents
Number of
responses per
respondent
Average
burden per
response
(in hours)
........................
Form
name
Type of respondent
........................
........................
Dated: October 28, 2014.
Michelle Trout,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2014–26025 Filed 10–31–14; 8:45 am]
BILLING CODE 4140–01–P
[FR Doc. 2014–26030 Filed 10–31–14; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institutes of Health
National Cancer Institute; Notice of
Meeting
National Institute on Drug Abuse;
Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the Joint meeting of
the National Cancer Advisory Board
(NCAB) and NCI Board of Scientific
Advisors (BSA).
The meeting will be open to the
public as indicated below, with
attendance limited to space available.
Individuals who plan to attend and
need special assistance, such as sign
language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
A portion of the Joint NCAB/BSA
meeting will be closed to the public in
accordance with the provisions set forth
in section 552b(c)(6), Title 5 U.S.C., as
amended for the review, discussion, and
evaluation of individual intramural
programs and projects conducted by the
National Cancer Institute, including
consideration of personnel qualification
and performance, and the competence
of individual investigators, the
disclosure of which would constitute a
clearly unwarranted invasion of
personal privacy.
mstockstill on DSK4VPTVN1PROD with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of a meeting of the Board
of Scientific Counselors, NIDA.
The meeting will be closed to the
public as indicated below in accordance
with the provisions set forth in section
552b(c)(6), Title 5 U.S.C., as amended
for the review, discussion, and
evaluation of individual intramural
programs and projects conducted by the
National Institute on Drug Abuse,
including consideration of personnel
qualifications and performance, and the
competence of individual investigators,
the disclosure of which would
constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Board of Scientific
Counselors, NIDA.
Date: November 20, 2014.
Closed: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate personal
qualifications and performance, and
competence of individual investigators.
Place: Intramural Research Program,
National Institute on Drug Abuse, NIH, Johns
Hopkins Bayview Campus, Baltimore, MD
21223.
Contact Person: Joshua Kysiak, Program
Specialist, Biomedical Research Center,
Intramural Research Program, National
Institute on Drug Abuse, NIH, DHHS, 251
Bayview Boulevard, Baltimore, MD 21224,
443–740–2465, kysiakjo@nida.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos.: 93.279, Drug Abuse and
Addiction Research Programs, National
Institutes of Health, HHS)
VerDate Sep<11>2014
17:37 Oct 31, 2014
Jkt 235001
Name of Committee: National Cancer
Advisory Board; ad Hoc Subcommittee on
Global Cancer Research.
Open: December 1, 2014, 6:00 p.m. to 7:30
p.m.
Agenda: Discussion on Global Cancer
Research.
Place: Hyatt Regency Bethesda, One
Bethesda Metro Center, Bethesda, Maryland
20814.
Contact Person: Dr. Edward Trimble,
Executive Secretary, NCAB ad Hoc
Subcommittee on Global Cancer Research,
National Cancer Institute, National Institutes
of Health, 9609 Medical Center Drive, Room
PO 00000
Frm 00047
Fmt 4703
Sfmt 4703
Total burden
hours
1,386
3W–562, Bethesda, MD 20892, (240) 276–
5796, trimblet@mail.nih.gov.
Name of Committee: National Cancer
Advisory Board and NCI Board of Scientific
Advisors.
Open: December 2, 2014, 8:30 a.m. to 5:15
p.m.
Agenda: Joint meeting of the National
Cancer Advisory Board; and NCI Board of
Scientific Advisors; NCI Board of Scientific
Advisors Concepts Review, NCI Director’s
report, and presentations.
Place: National Institutes of Health, 9000
Rockville Pike, Building 31, C Wing, 6th
Floor, Conference Room 10, Bethesda, MD
20892.
Closed: December 2, 2014, 5:15 p.m. to
6:00 p.m.
Agenda: Review of intramural program site
visit outcomes and the discussion of
confidential personnel issues.
Place: National Institutes of Health, 9000
Rockville Pike, Building 31, C Wing, 6th
Floor, Conference Room 10, Bethesda, MD
20892.
Contact Person: Dr. Paulette S. Gray,
Executive Secretary, National Cancer
Institute, National Institutes of Health, 9606
Medical Center Drive, Room 7W–444,
Bethesda, MD 20892, (240) 276–6340.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
In the interest of security, NIH has
instituted stringent procedures for entrance
onto the NIH campus. All visitor vehicles,
including taxicabs, hotel, and airport shuttles
will be inspected before being allowed on
campus. Visitors will be asked to show one
form of identification (for example, a
government-issued photo ID, driver’s license,
or passport) and to state the purpose of their
visit. Information is also available on the
Institute’s/Center’s home page: NCAB:
https://deainfo.nci.nih.gov/advisory/ncab/
ncab.htm, BSA: https://deainfo.nci.nih.gov/
advisory/bsa/bsa.htm, where an agenda and
any additional information for the meeting
will be posted when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
E:\FR\FM\03NON1.SGM
03NON1
]]>Agencies
[Federal Register Volume 79, Number 212 (Monday, November 3, 2014)]
[Notices]
[Pages 65219-65221]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-26030]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[60-Day 15-15CK]
Proposed Data Collections Submitted for Public Comment and
Recommendations
The Centers for Disease Control and Prevention (CDC), as part of
its continuing effort to reduce public burden, invites the general
public and other Federal agencies to take this opportunity to comment
on proposed and/or continuing information collections, as required by
the Paperwork Reduction Act of 1995. To request more information on the
below proposed project or to obtain a copy of the information
collection plan and instruments, call 404-639-7570 or send comments to
Leroy A. Richardson, 1600 Clifton Road, MS-D74, Atlanta, GA 30333 or
send an email to omb@cdc.gov.
Comments submitted in response to this notice will be summarized
and/or included in the request for Office of Management and Budget
(OMB) approval. Comments are invited on: (a) Whether the proposed
collection of information is necessary for the proper performance of
the functions of the agency, including whether the information shall
have practical utility; (b) the accuracy of the agency's estimate of
the burden of the proposed collection of information; (c) ways to
enhance the quality, utility, and clarity of the information to be
collected; (d) ways to minimize the burden of the collection of
information on respondents, including through the use of automated
collection techniques or other forms of information technology; and (e)
estimates of capital or start-up costs and costs of operation,
maintenance, and purchase of services to provide information. Burden
means the total time, effort, or financial resources expended by
persons to generate, maintain, retain, disclose or provide information
to or for a Federal agency. This includes the time needed to review
instructions; to develop, acquire, install and utilize technology and
systems for the purpose of collecting, validating and verifying
information, processing and maintaining information, and disclosing and
providing information; to train personnel and to be able to respond to
a collection of information, to search data sources, to complete and
review the collection of information; and to transmit or otherwise
disclose the information. Written comments should be received within 60
days of this notice.
Proposed Project
Improving the Impact of Laboratory Practice Guidelines (LPGs): A
New Paradigm for Metrics--College of American Pathologists--NEW--Center
for Surveillance, Epidemiology and Laboratory Services (CSELS), Centers
for Disease Control and Prevention (CDC).
Background and Brief Description
The Centers for Disease Control and Prevention is funding three 5-
year projects collectively entitled ``Improving the Impact of
Laboratory Practice Guidelines: A New Paradigm for Metrics''. An
``LPG'' is defined as written recommendations for voluntary,
standardized approaches for medical laboratory testing that takes into
account processes for test selection, sample
[[Page 65220]]
procurement and processing, analytical methods, and results reporting
for effective diagnosis and management of disease and health
conditions. LPGs may be disseminated to, and used by, laboratorians and
clinicians to assist with test selection and test result
interpretation. The overall purpose of these cooperative agreements is
to increase the effectiveness of LPGs by defining measures and
collecting information to inform better LPG creation, revision,
dissemination, promotion, uptake, and impact on clinical testing and
public health. The project will explore how these processes and their
impediments and facilitators differ among various intended users of
LPGs. Through this demonstration project, CDC seeks to understand how
to customize LPG creation and promotion to better serve these intended
users of LPGs. An important goal is to help organizations that sponsor
the development of LPGs create a sustainable approach for continuous
quality improvement to evaluate and improve an LPG's impact through
better collection of information.
The CDC selected three organizations that currently create and
disseminate LPGs to support activities under a cooperative agreement
funding mechanism to improve the impact of their LPGs. The American
Society for Microbiology, the Clinical and Laboratory Standards
Institute, and the College of American Pathologists (CAP), will each
use their LPGs as models to better understand how to improve uptake and
impact of these and future LPGs. Only the CAP submission will be
described in this notice.
The CAP project will address two LPGs that are important to
clinical testing: immunohistochemistry test validation (IHC) and an
algorithm for diagnosing acute leukemia (ALA). The ALA LPG is being co-
developed with the American Society of Hematologists (ASH). The
intended users of the CAP's IHC LPGs will include pathologists,
clinical laboratory directors, and laboratory managers overseeing the
IHC staining department. For the CAP's ALA LPG the intended users are
pathologists and hematologists overseeing testing for acute leukemia.
Thus, all these professionals will be surveyed by CAP.
Prior to entering into this cooperative agreement project with the
CDC, the CAP had already completed a baseline IHC LPG information
collection from laboratories that used IHC testing. Subsequent to this
data collection, the CAP created and disseminated an IHC LPG in a peer
reviewed journal. Because of this prior baseline assessment, the CAP
will only need to collect post-dissemination data. For their ALA LPG
CAP/ASH Algorithm for Initial Work-Up of Acute Leukemia, the CAP will
conduct both a baseline and a post-dissemination survey. Because there
are uncertainties concerning the specific focus group probes for the
IHC LPG and the ALA LPG, this notice only provides a description of our
collection of post-dissemination information for the IHC LPG and the
baseline ALA LPG.
The CAP hopes to achieve an 80% response rate, or 2,668 out of
3,335 potential respondents. This represents laboratories known to be
currently performing IHC testing based upon their participation in
CAP's IHC proficiency testing (PT) program and 450 additional
laboratories identified by CDC using previous CMS Part B reimbursement
claims for IHC testing. The response rate for the baseline IHC survey
was approximately 70% but through more focused promotion the CAP hopes
to increase participation. We have identified a total of 3,335 (2,885
CAP-accredited + 450 non-CAP-accredited) laboratories that will be
targeted by the IHC post-dissemination survey.
CAP-accredited laboratories that are enrolled in IHC PT will
receive surveys with their PT mailings. Non-CAP-accredited laboratories
will be surveyed via the US postal system, with a fax-back mechanism.
The CAP will need to collect both baseline and post-guideline
dissemination data for the ALA LPG. CAP will allow only one response
per computer internet protocol address. The CAP has a database of
pathologists who have indicated specialization in hematopathology;
these hematopathologists will be invited to participate. The CAP hopes
to achieve an 80% response rate with their individual data collections,
or 880 (80% x 1100 pathologists listed in the CAP database).
The baseline survey for the ALA guideline includes questions about
individual practices for diagnosing various types of acute leukemia and
individual and laboratory reporting practices. The link to the baseline
survey for the ALA guideline will be disseminated via email to
hematopathologists in CAP's database, who will be provided a link to
the Qualtrics site that hosts the survey.
The CAP and CDC will strive to ensure a high response rate for
their IHC and ALA surveys. CAP plans to advertise both surveys.
Similarly, the CAP plans to maximize response rates for non-CAP-
accredited laboratories by sending reminders through the US postal
system. The CAP will also try to maximize response rates for the ALA
survey by advertising it through various channels.
For burden calculation, we assume one response per laboratory. We
assume respondents for the IHC survey will include (1) pathologists,
(2) laboratory directors, and (3) other laboratory managers of IHC
laboratories, which may consist of graduate level scientists (Ph.D.s
and Masters level), approximately in a 25%:25%:50% distribution,
respectively. We assume respondents for the ALA surveys will include
pathologists and hematologists that sign out cases, approximately in a
95%:5% distribution, respectively.
The IHC baseline survey, which was conducted prior to this CAP-CDC
cooperative agreement, took 15 minutes to complete. The IHC post-
dissemination survey and the ALA baseline survey are also expected to
take 15 minutes. Each survey will be pilot tested with nine or fewer
respondents before deployment to assure that they require 15 minutes or
less to complete. CDC is requesting a one-year OMB approval to collect
the information. There are no costs to respondents other than their
time.
Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
Number of Average burden
Type of respondent Form name Number of responses per per response Total burden
respondents respondent (in hours) hours
----------------------------------------------------------------------------------------------------------------
Pathologist....................... IHC 834 1 15/60 209
ALA 1,045 2 15/60 523
Laboratory Directors.............. IHC 834 1 15/60 209
Laboratory Managers............... IHC 1,667 1 15/60 417
Hematologist...................... ALA 55 2 15/60 28
---------------------------------------------------------------
[[Page 65221]]
Total......................... ............ .............. .............. .............. 1,386
----------------------------------------------------------------------------------------------------------------
Leroy A. Richardson,
Chief, Information Collection Review Office, Office of Scientific
Integrity, Office of the Associate Director for Science, Office of the
Director, Centers for Disease Control and Prevention.
[FR Doc. 2014-26030 Filed 10-31-14; 8:45 am]
BILLING CODE 4163-18-P
